Drug intelligence / Profile preview

Bifidobacterium longum CCFM1195

Development stage: Unknown
Lead developer: Wuxi People's Hospital
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Bifidobacterium longum CCFM1195 is a specific probiotic strain being investigated for its therapeutic potential in patients with end-stage renal disease (ESRD). Developed through a collaboration involving the Affiliated Wuxi People's Hospital of Nanjing Medical University and Jiangnan University, this live biotherapeutic product aims to mitigate the accumulation of uremic toxins, such as indoxyl sulfate and p-cresyl sulfate, which are typically elevated in renal failure. The mechanism of action involves the modulation of the gut microbiota to reduce the production of toxin precursors and the enhancement of the intestinal epithelial barrier to prevent toxin translocation. By addressing the gut-kidney axis, CCFM1195 seeks to improve clinical outcomes and quality of life for patients undergoing dialysis or managing advanced chronic kidney disease.

Other names: B. longum CCFM1195

Beyond the preview

Go deeper on Bifidobacterium longum CCFM1195.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bifidobacterium longum CCFM1195.

Explore the full profile